Amarin and Kowa Pharma to co-promote Vascepa in USA

1 April 2014

US biotech firm Amarin Corp (Nasdaq: AMRN) and Kowa Pharmaceuticals America, owned by Japan’s Kowa, have reached an agreement to co-promote Amarin's flagship product, Vascepa (icosapent ethyl) capsules, in the USA.

Vascepa is approved for use in the USA as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>= 500mg/dL) hypertriglyceridemia. In bringing together two companies focused on the primary care and cardiovascular health communities, the agreement is designed to benefit a greater number of patients.

Vascepa was launched by Amarin in early 2013. Sales of the drug in 2013 resulted in net revenues for Amarin of around $26.4 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK